Nanexa Management

Management Kriterienprüfungen 4/4

Nanexa's CEO ist David Westberg , ernannt in Jan 2015, hat eine Amtszeit von 9.42 Jahren. Die jährliche Gesamtvergütung beträgt SEK2.85M , bestehend aus 78.4% Gehalt und 21.6% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.27% der Aktien des Unternehmens, im Wert von SEK334.06K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 9.4 Jahre bzw. 3.1 Jahre.

Wichtige Informationen

David Westberg

Geschäftsführender

SEK 2.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	78.4%
Amtszeit als Geschäftsführer	9.7yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	9.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.3yrs

Jüngste Management Updates

Recent updates

How Much Does Nanexa's (STO:NANEXA) CEO Make?

Dec 09

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Westberg im Vergleich zu den Einnahmen von Nanexa verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-SEK 67m
Mar 31 2024	n/a	n/a	-SEK 71m
Dec 31 2023	SEK 3m	SEK 2m	-SEK 76m
Sep 30 2023	n/a	n/a	-SEK 43m
Jun 30 2023	n/a	n/a	-SEK 49m
Mar 31 2023	n/a	n/a	-SEK 55m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 59m
Sep 30 2022	n/a	n/a	-SEK 54m
Jun 30 2022	n/a	n/a	-SEK 50m
Mar 31 2022	n/a	n/a	-SEK 42m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 36m
Sep 30 2021	n/a	n/a	-SEK 31m
Jun 30 2021	n/a	n/a	-SEK 27m
Mar 31 2021	n/a	n/a	-SEK 25m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 22m
Sep 30 2020	n/a	n/a	-SEK 19m
Jun 30 2020	n/a	n/a	-SEK 18m
Mar 31 2020	n/a	n/a	-SEK 13m
Dec 31 2019	SEK 2m	SEK 1m	-SEK 13m
Sep 30 2019	n/a	n/a	-SEK 12m
Jun 30 2019	n/a	n/a	-SEK 11m
Mar 31 2019	n/a	n/a	-SEK 12m
Dec 31 2018	SEK 2m	SEK 1m	-SEK 11m
Sep 30 2018	n/a	n/a	-SEK 9m
Jun 30 2018	n/a	n/a	-SEK 9m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 8m

Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD272.83K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Swedish ($USD257.80K).

Entschädigung vs. Einkommen: DavidDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

David Westberg (64 yo)

9.7yrs

Amtszeit

SEK 2,847,000

Vergütung

Mr. David Westberg has been the Chief Executive Officer at Nanexa AB (publ) since 2015. Mr. Westberg serves as an Independent Director at Lipigon Pharmaceuticals AB (publ) since 2023. Mr. Westberg has expe...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Westberg	Chief Executive Officer	9.7yrs	SEK 2.85m	0.27% SEK 640.3k
Marten Rooth	Co-Founder	15.7yrs	keine Daten	0.33% SEK 762.5k
Anders Johansson	Co-Founder & Head of Intellectual Property	15.7yrs	SEK 996.00k	0.30% SEK 707.7k
Cecilia Danckwardt-Lilliestrom	Chief Financial Officer	no data	keine Daten	keine Daten
Mikael Asp	Head of QA & Expert Sakkunnig	4.3yrs	keine Daten	0.0027% SEK 6.2k
Joel Hellrup	Head of Pharmaceutical R&D	no data	keine Daten	0.0052% SEK 12.1k

9.7yrs

Durchschnittliche Betriebszugehörigkeit

48yo

Durchschnittliches Alter

Erfahrenes Management: NANEXADas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (9.4 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Birgit Norinder	Independent Director	3.3yrs	SEK 180.00k	0.044% SEK 103.5k
Goran Ando	Independent Chairman of the Board	4.7yrs	SEK 260.00k	0.77% SEK 1.8m
Robert Gale	Member of Advisory Board - NEX-18	no data	keine Daten	keine Daten
Eva Nilsagard	Independent Director	3.3yrs	SEK 230.00k	0.13% SEK 310.5k
Magnus Westgren	Independent Director	9.7yrs	SEK 130.00k	0.19% SEK 438.4k
Axel Glasmacher	Member of Advisory Board - NEX-18 & NEX-20	no data	keine Daten	keine Daten
Richard Davis	Independent Director	2.3yrs	SEK 130.00k	keine Daten
Kirsten Gronbaek	Member of Advisory Board - NEX-18	no data	keine Daten	keine Daten
Uwe Platzbecker	Member of Advisory Board - NEX-18	no data	keine Daten	keine Daten
Magnus Tobiasson	Member of Advisory Board - NEX-18	no data	keine Daten	keine Daten
Jose Miguel Diaz	Member of Advisory Board - NEX-18	no data	keine Daten	keine Daten
Xavier Leleu	Member of Advisory Board - NEX-20	no data	keine Daten	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

69yo

Durchschnittliches Alter

Erfahrener Vorstand: NANEXADie Vorstandsmitglieder gelten als erfahren (3.1 Jahre durchschnittliche Amtszeit).

Nanexa Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

Less than half of directors are independent

Recent updates

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Consensus revenue estimates increase by 32%

New minor risk - Financial position

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Consensus EPS estimates upgraded to kr0.42 loss

Price target decreased by 19% to kr4.95

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

Price target decreased to kr6.00

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

Price target decreased to kr7.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanexa AB Announces That the Company's Preclinical Investigation

Price target decreased to kr7.00

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

New 90-day low: kr10.20

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

How Much Does Nanexa's (STO:NANEXA) CEO Make?

New 90-day low: kr10.25

Third quarter 2020 earnings released: kr0.18 loss per share

New 90-day high: kr13.40

New 90-day high - kr13.35

First half earnings released

New 90-day high - kr11.80

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter